Paris-based Biomunex Pharmaceuticals, which has bispecific antibody technology, has appointed Sebastian Amigorena as scientific advisor to help develop its strategy in oncology. Dr Amigorena is a research director at France’s National Center for Scientific Research (CNRS) and director of the Inserm immunity and cancer unit at the Institut Curie in Paris. He specialises in immuno-oncology.
Separately, Biomunex has appointed Dragan Grabulovski as a strategic advisor. Dr Grabulovski is advisor to Grabulovski Consulting Services in Zurich, Switzerland. He was previously chief scientific officer and co-founder of Covagen AG, now part of Johnson & Johnson Inc.
Biomunex announced the appointments on 5 December 2016.
Copyright 2016 Evernow Publishing Ltd